This week we talk struggles with <a href="https://www.biospace.com/article/novo-warns-eu-of-glp-1-drug-shortages-expands-production-at-french-site-/ " target="_blank" rel="noopener noreferer">GLP-1 drug shortages</a> and what that might mean for Novo/Lilly competitors; Regeneron and Sanofi positive results for <a href="https://www.biospace.com/article/regeneron-and-sanofi-find-further-positive-results-for-dupixent-in-copd/ ">⁠⁠Dupixent⁠⁠</a> in COPD.
Plus, Merck <a href="https://www.biospace.com/article/merck-drops-up-to-610m-on-neuro-disease-focused-caraway-therapeutics-/ " target="_blank" rel="noopener noreferer">buys Caraway</a>, Beigene&#39;s <a href="https://www.biospace.com/article/beigene-inks-potential-1-3b-deal-with-ensem-for-early-stage-cdk2-inhibitor-/ " target="_blank" rel="noopener noreferer">deal</a> with Ensem, <a href="https://www.biospace.com/article/regeneron-and-sanofi-find-further-positive-results-for-dupixent-in-copd/ " target="_blank" rel="noopener noreferer">ups</a> and <a href="https://www.biospace.com/article/flagship-founded-microbiome-company-evelo-biosciences-throws-in-the-towel-/ " target="_blank" rel="noopener noreferer">downs</a> for Flagship. 
Join BioSpace&#39;s <a href="https://www.linkedin.com/in/lorielliskatz/" target="_blank" rel="noopener noreferer">Lori Ellis</a>, <a href="https://www.linkedin.com/in/greg-slabodkin-114a93/" target="_blank" rel="noopener noreferer">Greg Slabodkin</a> and <a href="https://www.linkedin.com/in/tyler-patchen-6bbb22a4/" target="_blank" rel="noopener noreferer">Tyler Patchen</a> as they discuss the most important biopharma news this week.

Artificial Intelligence, Part 2: Human Interaction, Liability, and Patient Safety

Unravel the business of science with BioSpace. We dive into biopharma's top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development.